("Inovio" or the "Company") (NASDAQ. INO) have opportunity to lead the securities fraud class action lawsuit ... (INO), CLICK HERE BEFORE APRIL 7, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
INO) ... (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application ...
INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.